Worth reading
44Recurring
Scored from 5 of 6 sectionsDirection
Mixed performance
Direction inferred from the company’s description.Scale
497
million yenWording
Avoiding a definitive answer
How definitive the wording is.Contents of this document
Earnings presentationFiscal year ending June 20266 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Operating profit-330 million yen
Full-year earnings forecast
Fiscal Period CoveredFiscal year ending June 2027
Business profitability
838 million yen
Operating profit
-461 million yen
Research and development costs
435 million yen
Number of medical institutions using Medcle
1,000 facilities
Monthly Medcle prescriptions
2,000 Requests/month
Number of development pipeline projects
11 Engagements
Number of contracted projects
17 Engagements
What the company explained in this material
New initiatives
- Launch of sales of Medcle, an app for treating insomnia disorders
- Launch of a website for healthcare professionals
- Launch of “Nemuri no Michishirube,” a disease-awareness website about insomnia
- Progress in the development of SMD105, SMD403, SMD106 and SMD107
- Clinical trial systems went live for clinical trials conducted by Heartseed and Kyorin Pharmaceutical
Key KPIsA metric the company considers important as a management benchmark.
- Number of development pipeline projects11 EngagementsYear on year against the same period last yearDown from 12 in the previous year
- Number of contracted projects15 EngagementsYear on year against the same period last yearDown from 16 in the previous year
- Number of employees51 people
- Number of patents obtained32 Engagements
- Cumulative number of projects adopted21 Engagements
- Cumulative number of joint research collaborations24 Companies/institutions
Unit price and quantity metricsThese figures show sales broken down by price and volume.
Number of medical institutions using Medcle
Forecast for the fiscal year ending June 20271,000 facilities
Monthly Medcle prescriptions
Forecast for the fiscal year ending June 20272,000 Requests/month
Reimbursement price
24,100 yen/prescription
Segment results
DTx product business
Business profitability
Fiscal year ended June 2025300 million yen
Full-year cumulative period ended June 2026340 million yen
Segment profit
Fiscal year ended June 2025118 million yen
Full-year cumulative period ended June 2026103 million yen
DTx platform business
Business profitability
Fiscal year ended June 2025162 million yen
Full-year cumulative period ended June 2026156 million yen
Segment profit
Fiscal year ended June 202533 million yen
Full-year cumulative period ended June 202676 million yen
Market Size / Share
- Domestic target market for apps treating insomnia disorders¥880 100 million
- Domestic potential market for apps treating insomnia disorders¥3,940 100 million
- SAM for apps treating insomnia disorders420 over ¥ hundred million
- Exercise therapy for breast cancer patients¥72 100 million
- ACP¥309 100 million
- Kidney rehabilitation¥660 100 million
Number of employees
Number of Employees51 people
As ofAugust 2026
| Item | Details |
|---|---|
| Document type | Earnings presentation |
| Fiscal Period Covered | Fiscal year ending June 2026 |
| Operating profit | -330 million yen |
| Full-year earnings forecast | Fiscal Period Covered Fiscal year ending June 2027 / Business profitability 838 million yen / Operating profit -461 million yen / Research and development costs 435 million yen / Number of medical institutions using Medcle 1,000 facilities / Monthly Medcle prescriptions 2,000 Requests/month / Number of development pipeline projects 11 Engagements / Number of contracted projects 17 Engagements |
| Segment results | DTx product business Business profitability Fiscal year ended June 2025 300 million yen / Full-year cumulative period ended June 2026 340 million yen / Segment profit Fiscal year ended June 2025 118 million yen / Full-year cumulative period ended June 2026 103 million yen / DTx platform business Business profitability Fiscal year ended June 2025 162 million yen / Full-year cumulative period ended June 2026 156 million yen / Segment profit Fiscal year ended June 2025 33 million yen / Full-year cumulative period ended June 2026 76 million yen |
| Key KPIs | Indicator name Number of development pipeline projects / Value 11 Engagements / Year on year against the same period last year Down from 12 in the previous year, Indicator name Number of contracted projects / Value 15 Engagements / Year on year against the same period last year Down from 16 in the previous year, Indicator name Number of employees / Value 51 people / Year on year against the same period last year Not disclosed, Indicator name Number of patents obtained / Value 32 Engagements / Year on year against the same period last year Not disclosed, Indicator name Cumulative number of projects adopted / Value 21 Engagements / Year on year against the same period last year Not disclosed, Indicator name Cumulative number of joint research collaborations / Value 24 Companies/institutions / Year on year against the same period last year Not disclosed |
| Unit price and quantity metrics | Number of medical institutions using Medcle Forecast for the fiscal year ending June 2027 1,000 facilities / Monthly Medcle prescriptions Forecast for the fiscal year ending June 2027 2,000 Requests/month / Reimbursement price Value 24,100 yen/prescription |
| Number of employees | Number of Employees 51 people / As of August 2026 |
| Market Size / Share | Market Domestic target market for apps treating insomnia disorders / Value ¥880 100 million, Market Domestic potential market for apps treating insomnia disorders / Value ¥3,940 100 million, Market SAM for apps treating insomnia disorders / Value 420 over ¥ hundred million, Market Exercise therapy for breast cancer patients / Value ¥72 100 million, Market ACP / Value ¥309 100 million, Market Kidney rehabilitation / Value ¥660 100 million |
| New initiatives | Launch of sales of Medcle, an app for treating insomnia disorders, Launch of a website for healthcare professionals, Launch of “Nemuri no Michishirube,” a disease-awareness website about insomnia, Progress in the development of SMD105, SMD403, SMD106 and SMD107, Clinical trial systems went live for clinical trials conducted by Heartseed and Kyorin Pharmaceutical |
Items this document does not state (21)
Net SalesOrdinary incomeNet incomeGross Profit MarginOperating profit marginSelling, general and administrative expensesResults for the three months of the current quarterProgress against full-year forecastSelf-assessment against the planBreakdown of Factors Affecting the ChangeNumber of stores and locationsAssumptions Underlying the Business OutlookRisk amount incorporated into the outlookMedium-term management plan targetsFinancial targetsAnnual DividendPayout ratioAcquisition of treasury sharesCapital expendituresOrders received and order backlogKey points of the Q&A
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The increase in business revenue was attributable to contributions from milestone revenue and steady performance in the DTx platform business. The operating loss and its expansion were due to higher personnel costs associated with stepped-up hiring and promotional expenses related to the launch of Medcle sales. For the fiscal year ending June 2027, the company expects revenue growth from Medcle sales, milestone income from its pipeline, and steady performance in the platform business, while also anticipating higher expenses for office relocation, personnel costs resulting from continued hiring, and research and development associated with the start of multiple clinical trials.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.